Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Chiron Buys Discovery Firm
July 12, 2004
| A version of this story appeared in
Volume 82, Issue 28
In an effort to advance work in cancer and on small-molecule drugs, Chiron has acquired Sagres Discovery, a privately held drug discovery company, for an undisclosed sum. "With the wealth of targets from Sagres, we expect to be able to maximize the value of our collaboration with Xoma and our small-molecule drug discovery program for the development and commercialization of new drugs for the treatment of cancer," states Kenneth W. Bair, Chiron's senior vice president of research. Chiron and Xoma entered an antibody-based cancer therapy collaboration earlier this year (C&EN, March 8, page 14).
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X